AU2021382658A1 - Anti-marco antibodies and uses thereof - Google Patents

Anti-marco antibodies and uses thereof Download PDF

Info

Publication number
AU2021382658A1
AU2021382658A1 AU2021382658A AU2021382658A AU2021382658A1 AU 2021382658 A1 AU2021382658 A1 AU 2021382658A1 AU 2021382658 A AU2021382658 A AU 2021382658A AU 2021382658 A AU2021382658 A AU 2021382658A AU 2021382658 A1 AU2021382658 A1 AU 2021382658A1
Authority
AU
Australia
Prior art keywords
antibody
sequence
seq
cdr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021382658A
Other languages
English (en)
Inventor
Linnea Haeggblom
Nadine JAHCHAN
Vladislava Juric
Linda Liang
Sayantan Mitra
Kara Mojica
Joshua Pollack
Leonard G. Presta
Venkataraman SRIRAM
Michel Streuli
Xi Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pionyr Immunotherapeutics Inc
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of AU2021382658A1 publication Critical patent/AU2021382658A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021382658A 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof Pending AU2021382658A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063115272P 2020-11-18 2020-11-18
US63/115,272 2020-11-18
US202163244662P 2021-09-15 2021-09-15
US63/244,662 2021-09-15
PCT/US2021/059955 WO2022109178A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021382658A1 true AU2021382658A1 (en) 2023-07-06

Family

ID=81588283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021382658A Pending AU2021382658A1 (en) 2020-11-18 2021-11-18 Anti-marco antibodies and uses thereof

Country Status (10)

Country Link
US (2) US11572407B2 (https=)
EP (1) EP4247419A4 (https=)
JP (1) JP2023549555A (https=)
KR (1) KR20230121759A (https=)
AU (1) AU2021382658A1 (https=)
CA (1) CA3198579A1 (https=)
IL (1) IL302874A (https=)
MX (1) MX2023005841A (https=)
TW (1) TW202237648A (https=)
WO (1) WO2022109178A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11572407B2 (en) 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof
CA3238769A1 (en) * 2021-11-23 2023-06-01 William Brondyk Anti-ngf antibodies and uses thereof
WO2024059256A1 (en) * 2022-09-15 2024-03-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
WO2024081807A2 (en) * 2022-10-12 2024-04-18 Massachusetts Institute Of Technology Library-scale methods for polypeptide functional analysis
WO2025102054A1 (en) * 2023-11-09 2025-05-15 Massachusetts Institute Of Technology Methods of screening for secreted functional molecules

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916766A (en) 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
JP2010534335A (ja) * 2007-07-24 2010-11-04 アイエスエス イミューン システム スティミュレーション アーベー 全身性エリテマトーデス感受性を予測するための方法及び手段
WO2009114547A2 (en) 2008-03-10 2009-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
KR20130108295A (ko) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP3302558A4 (en) 2015-06-01 2019-01-16 The Rockefeller University ANTI-TUMOR MEDIUM AND METHOD OF USE
WO2017062363A1 (en) 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CN110709422B (zh) 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
TWI828625B (zh) 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
EP3668899A4 (en) 2017-08-18 2020-09-02 Celdara Medical, LLC CELL-BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE DISEASES
WO2019068007A1 (en) 2017-09-28 2019-04-04 Immpact-Bio Ltd. UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
US20210000920A1 (en) 2017-12-22 2021-01-07 Atossa Therapeutics, Inc. Intraductal methods of treatment of breast disorders
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
AU2019394364A1 (en) * 2018-12-05 2021-06-17 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses therefor
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
JP2022519378A (ja) 2019-02-08 2022-03-23 グッド ティー セルズ、 インコーポレイテッド がん治療のためのｔ細胞の活性化方法
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
JP2022536598A (ja) 2019-05-07 2022-08-18 イミューニコム， インコーポレイテッド 体外アフェレーシスによるチェックポイント阻害剤に対する応答の上昇
JP2022536684A (ja) 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
EP4003994A4 (en) 2019-07-31 2023-09-13 Oncour Pharma, Inc. TREATMENT OF EVASIVE IMMUNE TUMORS
US11572407B2 (en) 2020-11-18 2023-02-07 Pionyr Immunotherapeutics, Inc. Anti-MARCO antibodies and uses thereof

Also Published As

Publication number Publication date
US11572407B2 (en) 2023-02-07
IL302874A (en) 2023-07-01
US20220153832A1 (en) 2022-05-19
MX2023005841A (es) 2023-08-16
CA3198579A1 (en) 2022-05-27
EP4247419A4 (en) 2024-11-06
KR20230121759A (ko) 2023-08-21
TW202237648A (zh) 2022-10-01
US12378311B2 (en) 2025-08-05
WO2022109178A1 (en) 2022-05-27
US20240084000A1 (en) 2024-03-14
JP2023549555A (ja) 2023-11-27
EP4247419A1 (en) 2023-09-27
WO2022109178A9 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Ｃｄ７３特異的結合分子及びその使用
US12378311B2 (en) Anti-MARCO antibodies and uses thereof
CN109476732B (zh) 三特异性和/或三价结合蛋白
JP7688579B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP7759996B2 (ja) 抗ｔｒｅｍ１抗体及び関連方法
US12065491B2 (en) Anti-TREM1 antibodies and related methods
CN114075288B (zh) 抗pd-l2抗体
HK40096227A (zh) 抗marco抗体和其用途
EA052033B1 (ru) Антитела к marco и их применение
CN116635073A (zh) 抗marco抗体和其用途
AU2020203065B2 (en) Modified CK and CH1 domains
HK40065337A (en) Anti-trem1 antibodies and related methods
JP2024544386A (ja) Ｐｄ－ｌ１抗原結合タンパク質及びその使用
Nilvebrant et al. IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of the Antibody Society, December 5–8, 2011, San Diego, CA
CA3230742A1 (en) Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf.beta. and uses thereof
EA049996B1 (ru) Антитело к siglec-10 (варианты)